Form 6-K Calliditas Therapeutics For: Jul 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Calliditas Therapeutics AB (CALT) Gains on EU Licensing Deal
July 21, 2021 10:26 AM EDTOn July 21st, 2020, Calliditas Therapeutics AB (NASDAQ: CALT) announced that it has entered into a licensing agreement with STADA Arzneimittel AG ("STADA") for EU commercialization of Nefecon CALTs novel drug candidate with the potential to become the first EU approved treatment for Bergers disease.
Under the terms of the agreement, Calliditas is entitled to receive an initial upfront payment of 20M EUR ($24m) upon signing and up to an additional 77.5M EUR ($91m) in future... More
